Effects of the angiotensin receptor blocker Valsartan (Valsacor^®) on arterial pressure, indices of myocardial diastolic function and global longitudinal strain in patients with uncontrolled arterial hypertension

English version České info

The objective of this study was to evaluate the effects of Valsartan (Valsacor^®) on arterial pressure (AP) and indices of myocardial diastolic and global function in patients with uncontrolled arterial hypertension (AH).

Material and methods:
60 patients (39 men and 21 women, mean age 63.9 ± 10.8 years, P > 140/90 mmHg with a background of combined antihypertensive therapy) were involved in the study. Valsartan (Valsacor^®) was added to the standard therapy. The follow-up continued for three months, with clinical visits at initiation and completion of the study. The echocardiographic (EchoCG) evaluation included measurements of left ventricular and left atrial dimensions and function via longitudinal strain and Doppler-analysis of the transmitral blood flow.

Results:
The administration of Valsartan (Valsacor^®) resulted in a significant improvement in the antihypertensive control in the studied patients. The mean values of the baseline systolic blood (SBP) and diastolic blood (DBP) pressure in the studied group of patients were 174.9 ± 17.9 (range 150–230) mmHg and 97.5 ± 6.4 (range 85–110) mmHg, respectively. The mean SBP and DBP values at the end of the third month of the follow-up period were 139.1 ± 10.9 (range 120–180) mmHg and 84.9 ± 6.2 mmHg, respectively, at p < 0.05, compared to the baseline. The results of the echocardiographic analysis revealed significant differences in the dynamic performance of the indices: telesystolic dimension of the left ventricle, deceleration time (DT), E‘, E/E‘ ratio and values of longitudinal strain. The observed dynamic performance reflects favourable responses of the indices for diastolic function and longitudinal strain in the studied patients.

Conclusion:
Valsartan (Valsacor^®), used as an adjunct to the standard antihypertensive therapy in patients with insufficiently controlled AH, leads to optimisation of the AP values and improvement of the indices of diastolic and global myocardial function, with a very good safety profile.

Keywords:
Valsartan – arterial hypertension – diastolic dysfunction –strain

Autoři: K. Vitlyanova; Naidenov St.; N. Runev; E. Manov; R. Shabani; Y. Rangelov; K. Koshtikova; T. Donova
Působiště autorů: Clinic of Cardiology, Clinic of Propedeutics of Internal Diseases “Prof. Dr. S. Kirkovich”, Department of Cardiology, Medical University Sofia
Vyšlo v časopise: Vnitř Lék 2013; 59(12): 1124-1129
Kategorie: Aktualita

Souhrn

Keywords:
Valsartan – arterial hypertension – diastolic dysfunction –strain

Zdroje

1. Daskalov I. Terapia s angiotenzin receptorni blokeri. Medinfo, Sofia 2008; 9: godina VIII.

2. 2003 European Society of Hypertension / European Society of Cardiology Guidelines for the management of Arterial Hypertension. J. Hypertens 2003; 21: 1011–1153.

3. 2003 Word Health Organisation / International Society of Hypertension. Statement Management of Hypertension. J.Hypertens 2003; 21: 1983–1892.

4. World Health Report, 2002.

5. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.The National High Blood Pressure Education Program Coordinating Committee. Hypertension. 2003; 42: 1206–1252.

6. Nagueh SF, Appleton C, Gillebert TC. Reccomendations for the evaluation of LV diastolic function by echocardiography; Eur J Echocardiogr 2009; 10: 165–193

7. Catanzaro D., Frishman W. Angiotensin receptor blockers for management of hypertension. South Med J 2010; 103: 669–673.

8. Ho CY, Solomon SD. A Clinician’s Guide to Tissue Doppler Imaging. Circulation 2006; 113: e396–e398.

9. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:1810.

10. Hunt SA, Abraham WT, Chin MH et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119:e391.

11. Wachtell K, Bella JN, Rokkedal J et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 2002; 105: 1071–1076.

12. Dahlöf B, Devereux RB, Kjeldsen SE et al, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.

13. Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41–46.

14. Sun JP, Stewart WJ, Yang XS et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol 2009; 103: 411–415.

15. Cho GY, Marwick TH, Kim HS et al. Global 2-dimensional strain as a new prognosticator in patients with heart failure. J Am Coll Cardiol 2009; 54: 618–624.

16. Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging 2009; 2: 356–364.

17. Nguyen JS, Lakkis NM, Bobek J et al. Systolic and Diastolic Myocardial Mechanics in Patients with Cardiac Disease and Preserved Ejection Fraction: Impact of Left Ventricular Filling Pressure. J Am Soc Echocardiogr. 2013; 23: 1273–1280.